thiazolidinediones


Also found in: Dictionary, Acronyms.
Related to thiazolidinediones: Biguanides, meglitinides

thiazolidinediones

A class of drugs used to combat INSULIN RESISTANCE in patients with Type 2 DIABETES. These drugs are insulin sensitizing agents and act by binding selectively to preoxisome-proliferator-activated gamma receptors (PPAR). These regulate gene expression in response to binding.
References in periodicals archive ?
(19) If the target is not reached on monotherapy or dual therapy, one of the following treatment options can be considered: sulfonylurea, SGLT-2 inhibitor, thiazolidinedione, GLP-1 receptor agonist, DPP-4 inhibitor, or basal insulin.
Mello et al., "Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor [gamma]-independent regulation of nucleophosmin," Hepatology, vol.
Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-Ll cells.
Certain members of the thiazolidinediones family of the peroxisome proliferator-activated receptor (PPAR[gamma]) agonists, such as TG and ciglitazone, possess a beneficial action against ROS, inflammation, and adipocytokine dysregulation [23, 24].
The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes.
The structure - activity relationship between peroxisome proliferator-activated receptor agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996;39:665- 8.
Medicaid Managed Care: Disparities in the Use of Thiazolidinediones Compared with Metformin.
Pioglitazone and rosiglitazone belong to a class of drugs called thiazolidinediones that help to control blood sugar levels in patients with type 2 diabetes.
SAN FRANCISCO -- Evidence continues to mount that thiazolidinediones decrease bone density and increase fracture risk in patients with diabetes, but there are no randomized studies to show that adding an antiresorptive drug would protect bone health in this setting.
It will be available to new patients only if they are unable to achieve glucose control on other medications and are unable to take pioglitazone the only other medication of thiazolidinediones. Current users of rosiglitazone who are benefitting from the medicine will be able to continue using the medication if they chose to do so.
The thiazolidinediones are well studied in adults, where they reduce [HbA.sub.lc] by about 1% and might prolong beta-cell function, a highly desirable attribute in a teenager who may be living with type 2 diabetes for another 50 years.